{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-like+peptide+1+receptor+agonist&page=7",
    "query": {
      "intervention": "Glucagon-like peptide 1 receptor agonist",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 160,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-like+peptide+1+receptor+agonist&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-like+peptide+1+receptor+agonist&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T00:31:59.971Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02057172",
      "title": "Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "HM11260C",
          "type": "DRUG"
        },
        {
          "name": "liraglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hanmi Pharmaceutical Company Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 254,
      "start_date": "2014-01",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2016-08-09",
      "last_synced_at": "2026-10-14T00:31:59.971Z",
      "location_count": 1,
      "location_summary": "CA, California",
      "locations": [
        {
          "city": "CA",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02057172"
    },
    {
      "nct_id": "NCT07220473",
      "title": "Tirzepatide to Slow Biological Aging",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Aging",
        "LONGEVITY 1"
      ],
      "interventions": [
        {
          "name": "Zepbound",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "55 Years to 70 Years"
      },
      "enrollment_count": 90,
      "start_date": "2026-02-27",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-10-14T00:31:59.971Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07220473"
    },
    {
      "nct_id": "NCT02324842",
      "title": "Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Canagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Liraglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 45,
      "start_date": "2014-11",
      "completion_date": "2019-03-31",
      "has_results": true,
      "last_update_posted_date": "2019-12-18",
      "last_synced_at": "2026-10-14T00:31:59.971Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02324842"
    },
    {
      "nct_id": "NCT06682351",
      "title": "Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Prediabetes / Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "GLP-1A",
          "type": "DRUG"
        },
        {
          "name": "MED",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 200,
      "start_date": "2024-11",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2024-11-12",
      "last_synced_at": "2026-10-14T00:31:59.971Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06682351"
    },
    {
      "nct_id": "NCT03279731",
      "title": "Binge Eating Liraglutide Intervention",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Binge-Eating Disorder"
      ],
      "interventions": [
        {
          "name": "Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kelly Allison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "21 Years to 70 Years"
      },
      "enrollment_count": 36,
      "start_date": "2017-09-29",
      "completion_date": "2019-10-01",
      "has_results": true,
      "last_update_posted_date": "2020-11-24",
      "last_synced_at": "2026-10-14T00:31:59.971Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03279731"
    },
    {
      "nct_id": "NCT06515418",
      "title": "Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Oral Azelaprag (BGE-105)",
          "type": "DRUG"
        },
        {
          "name": "Oral Placebo for Azelaprag (BGE-105)",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioAge Labs, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 204,
      "start_date": "2024-06-27",
      "completion_date": "2025-02-12",
      "has_results": false,
      "last_update_posted_date": "2025-03-13",
      "last_synced_at": "2026-10-14T00:31:59.971Z",
      "location_count": 14,
      "location_summary": "Mesa, Arizona • Los Angeles, California • Montclair, California + 11 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Montclair",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06515418"
    },
    {
      "nct_id": "NCT04034524",
      "title": "Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "GLP-1 receptor agonist",
          "type": "DRUG"
        },
        {
          "name": "Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20000,
      "start_date": "2019-05-01",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-07-09",
      "last_synced_at": "2026-10-14T00:31:59.971Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04034524"
    },
    {
      "nct_id": "NCT06581120",
      "title": "GLP_1 RA Ultrasound Study",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glucagon Like Peptide-1 (GLP-1",
        "Delayed Gastric Emptying",
        "Risk of Aspiration",
        "Diabetes",
        "Morbid Obesity"
      ],
      "interventions": [
        {
          "name": "Glucagon-Like Peptide-1 receptor agonists",
          "type": "DRUG"
        },
        {
          "name": "Point of Care Gastric Ultrasound",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "10 Years to 25 Years"
      },
      "enrollment_count": 100,
      "start_date": "2024-07-08",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2024-11-07",
      "last_synced_at": "2026-10-14T00:31:59.971Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06581120"
    },
    {
      "nct_id": "NCT04019197",
      "title": "Effects of Semaglutide in HIV-Associated Lipohypertrophy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV/AIDS",
        "Lipohypertrophy",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Semaglutide Injectable Product",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Western Reserve University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2019-05-16",
      "completion_date": "2026-09-01",
      "has_results": true,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-10-14T00:31:59.971Z",
      "location_count": 2,
      "location_summary": "Cleveland, Ohio • Charleston, South Carolina",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04019197"
    },
    {
      "nct_id": "NCT07797036",
      "title": "Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Gestational Diabetes Mellitus (GDM)",
        "Metabolic Syndrome"
      ],
      "interventions": [
        {
          "name": "Semaglutide (Wegovy) weekly injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Massachusetts, Worcester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 226,
      "start_date": "2027-09-01",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-14T00:31:59.971Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07797036"
    }
  ]
}